A Phase 1 Study of PKI-179 Administered Orally to Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs PKI 179 (Primary)
- Indications Breast cancer; Colorectal cancer; Endometrial cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- 03 Dec 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Oct 2009 New trial record